FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Agonists/antagonists of steroid receptors and bisphosponates in estrogen replacement therapy: Molecular-chemical basis

Agonisti/antagonisti steroidnih receptora i bisfosfonati u supstitucionoj terapiji - molekularno-hemijske osnove

Thumbnail
2005
597.pdf (303.3Kb)
Authors
Agbaba, Danica
Vladimirov, Sote
Article (Published version)
Metadata
Show full item record
Abstract
Agonists of estrogen receptors, such as esters of estradiol, conjugated estrogens and esterified estrogens have been widely used in estrogen replacement therapy. Partial agonists of estrogen receptors, derivatives of triarylethylene such as, tamoxifen and toremifene posses weak estrogen-like effects on endometrium, bone and lipids. Recent advances in molecular pharmacology and estrogen receptors have resulted in the development of selective receptor modulators (SEMSs) that activate the estrogen receptor but that also exhibit tissue-specific estrogen-agonist or -antagonist activity. The first SERM marked is the benzothiophene, raloxifene which was introduced to maintain bone density in controlling osteoporosis postmenopausal women. Bisphosphonates have been used as second-line agents for prevention and treatment of osteoporosis in postmenopausal women.
U supstitucionoj terapiji kod žena koriste se hormoni steroidne strukture/ agonisti ERa i ERp estrogenih receptora: derivati estrana, estri estradiola, metaboliti estardiola - prirodni proizvodi konjugovani estrogeni i polusintetski -esterifikovani estrogeni. Pored agonista u terapiji se koriste i parcijalni agonisti steroidnih receptora, derivati trifeniletilena ili trifeniletana kao što su tamoksifen i toreksifen. Derivat rigidne biciklične strukture-benzotiofena, raloksifen, je selektivni modulator estrogenih receptora, agonista estrogenih receptora u osteoblastima i osteoklastima, a antagonista na estrogenim receptorima uterusa i dojke. U terapiji osteoporoze se koriste hemijski stabilni bisfosfonati kao što su alendronat, risendronat i dr.
Keywords:
estrogens steroid structures / conjugated estrogens / esterified estrogens / derivatives of triarylethylene / selective receptor modulators / estrogeni steroidne strukture / konjugovani i esterifikovani estrogeni / derivati trifeniletilena / selektivni modulatori estrogenih receptora
Source:
Arhiv za farmaciju, 2005, 55, 2, 120-130
Publisher:
  • Savez farmaceutskih udruženja Srbije, Beograd

ISSN: 0004-1963

[ Google Scholar ]
Handle
https://hdl.handle.net/21.15107/rcub_farfar_599
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/599
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Agbaba, Danica
AU  - Vladimirov, Sote
PY  - 2005
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/599
AB  - Agonists of estrogen receptors, such as esters of estradiol, conjugated estrogens and esterified estrogens have been widely used in estrogen replacement therapy. Partial agonists of estrogen receptors, derivatives of triarylethylene such as, tamoxifen and toremifene posses weak estrogen-like effects on endometrium, bone and lipids. Recent advances in molecular pharmacology and estrogen receptors have resulted in the development of selective receptor modulators (SEMSs) that activate the estrogen receptor but that also exhibit tissue-specific estrogen-agonist or -antagonist activity. The first SERM marked is the benzothiophene, raloxifene which was introduced to maintain bone density in controlling osteoporosis postmenopausal women. Bisphosphonates have been used as second-line agents for prevention and treatment of osteoporosis in postmenopausal women.
AB  - U supstitucionoj terapiji kod žena koriste se hormoni steroidne strukture/ agonisti ERa i ERp estrogenih receptora: derivati estrana, estri estradiola, metaboliti estardiola - prirodni proizvodi konjugovani estrogeni i polusintetski -esterifikovani estrogeni. Pored agonista u terapiji se koriste i parcijalni agonisti steroidnih receptora, derivati trifeniletilena ili trifeniletana kao što su tamoksifen i toreksifen. Derivat rigidne biciklične strukture-benzotiofena, raloksifen, je selektivni modulator estrogenih receptora, agonista estrogenih receptora u osteoblastima i osteoklastima, a antagonista na estrogenim receptorima uterusa i dojke. U terapiji osteoporoze se koriste hemijski stabilni bisfosfonati kao što su alendronat, risendronat i dr.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Agonists/antagonists of steroid receptors and bisphosponates in estrogen replacement therapy: Molecular-chemical basis
T1  - Agonisti/antagonisti steroidnih receptora i bisfosfonati u supstitucionoj terapiji - molekularno-hemijske osnove
VL  - 55
IS  - 2
SP  - 120
EP  - 130
UR  - https://hdl.handle.net/21.15107/rcub_farfar_599
ER  - 
@article{
author = "Agbaba, Danica and Vladimirov, Sote",
year = "2005",
abstract = "Agonists of estrogen receptors, such as esters of estradiol, conjugated estrogens and esterified estrogens have been widely used in estrogen replacement therapy. Partial agonists of estrogen receptors, derivatives of triarylethylene such as, tamoxifen and toremifene posses weak estrogen-like effects on endometrium, bone and lipids. Recent advances in molecular pharmacology and estrogen receptors have resulted in the development of selective receptor modulators (SEMSs) that activate the estrogen receptor but that also exhibit tissue-specific estrogen-agonist or -antagonist activity. The first SERM marked is the benzothiophene, raloxifene which was introduced to maintain bone density in controlling osteoporosis postmenopausal women. Bisphosphonates have been used as second-line agents for prevention and treatment of osteoporosis in postmenopausal women., U supstitucionoj terapiji kod žena koriste se hormoni steroidne strukture/ agonisti ERa i ERp estrogenih receptora: derivati estrana, estri estradiola, metaboliti estardiola - prirodni proizvodi konjugovani estrogeni i polusintetski -esterifikovani estrogeni. Pored agonista u terapiji se koriste i parcijalni agonisti steroidnih receptora, derivati trifeniletilena ili trifeniletana kao što su tamoksifen i toreksifen. Derivat rigidne biciklične strukture-benzotiofena, raloksifen, je selektivni modulator estrogenih receptora, agonista estrogenih receptora u osteoblastima i osteoklastima, a antagonista na estrogenim receptorima uterusa i dojke. U terapiji osteoporoze se koriste hemijski stabilni bisfosfonati kao što su alendronat, risendronat i dr.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Agonists/antagonists of steroid receptors and bisphosponates in estrogen replacement therapy: Molecular-chemical basis, Agonisti/antagonisti steroidnih receptora i bisfosfonati u supstitucionoj terapiji - molekularno-hemijske osnove",
volume = "55",
number = "2",
pages = "120-130",
url = "https://hdl.handle.net/21.15107/rcub_farfar_599"
}
Agbaba, D.,& Vladimirov, S.. (2005). Agonists/antagonists of steroid receptors and bisphosponates in estrogen replacement therapy: Molecular-chemical basis. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 55(2), 120-130.
https://hdl.handle.net/21.15107/rcub_farfar_599
Agbaba D, Vladimirov S. Agonists/antagonists of steroid receptors and bisphosponates in estrogen replacement therapy: Molecular-chemical basis. in Arhiv za farmaciju. 2005;55(2):120-130.
https://hdl.handle.net/21.15107/rcub_farfar_599 .
Agbaba, Danica, Vladimirov, Sote, "Agonists/antagonists of steroid receptors and bisphosponates in estrogen replacement therapy: Molecular-chemical basis" in Arhiv za farmaciju, 55, no. 2 (2005):120-130,
https://hdl.handle.net/21.15107/rcub_farfar_599 .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB